← All trials
NCT00067119
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2003
- Primary completion
- Jan 1, 2003
- Completion date
- Feb 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 1284
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Lead sponsor
- Boston UniversityCollaborator
- Duke UniversityCollaborator
- University of IowaCollaborator
- Vanderbilt UniversityCollaborator
- CAMC Health SystemCollaborator
- Emory UniversityCollaborator
- St. Louis UniversityCollaborator
- Tufts UniversityCollaborator
- University of MassachusettsCollaborator
- Tyler Nephrology AssociatesCollaborator
- Vascular Surgery Associates LLCCollaborator
- Washington University in St. LouisCollaborator
- National Institutes of Health (NIH)Study director
- University of Alabama, BirminghamCollaborator
- University of RochesterCollaborator
- The University of Texas, DallasCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.